Who are Centauri Therapeutics's investors?

Centauri Therapeutics's investors include AMR Action Fund, NCL Technology Ventures Ltd., Boehringer Ingelheim Venture Fund.

Centauri Therapeutics

3 known investors

Find your way into Centauri Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Centauri Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets. The platform is intended for treatment of life-threatening indications across multiple disease areas.

Biotech Digital Health Healthtech Medical Devices

Investors · 3

AMR Action Fund✓ confirmed by Centauri TherapeuticsBoston

How we know: the company's own site · AMR Action Fund's portfolio page · funding news · press coverage · Not right? Tell us

NCL Technology Ventures Ltd.listed by NCL Technology Ventures Ltd.London

How we know: NCL Technology Ventures Ltd.'s portfolio page · Not right? Tell us

Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

How we know: press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries A ExtensionFeb 2026
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗

Registered name: CENTAURI THERAPEUTICS LIMITED
Company number: 08879741
Status: Active
Company type: Private limited company
Incorporated: 6 Feb 2014
Registered office: First Floor, 5 Fleet Place, London, EC4M 7RD
Nature of business (SIC): 96090 — Other service activities n.e.c.
Previous names: ALTERMUNE LIMITED (2015–2015)ALTERMET LIMITED (2014–2015)
Accounts: last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement: last made up to 6 Feb 2026 · next due 20 Feb 2027

Current officers · 7

Antonio Felici — director, appointed 9 Jun 2025
Camilla Petrycer Hansen — director, appointed 26 Jan 2022
Sebastian Tobias Kreuz — director, appointed 31 Jan 2025
Stuart John Lawson — director, appointed 6 Feb 2014
David Roblin — director, appointed 1 May 2022
Henni-Karoliina Ropponen — director, appointed 7 Jan 2026
Jennifer Robin Schneider — director, appointed 1 Sept 2021

Source: Companies House public register · retrieved 7 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Investors - Centauri Therapeutics Limitedcentauritherapeutics.com · May 2026

Centauri Therapeutics Extends Series A to £30M With £6M Investment From AMR Action Fund to Support Progression of Lead Clinical Candidate - BioSpacebiospace.com · Feb 2026

Centauri Therapeutics Raises £6M in Series A Extension Fundingfinsmes.com · Feb 2026

Centauri Therapeutics gets £1M grant to fuel future of immune-powered anti-infectives — TFNtechfundingnews.com · Nov 2024

Frequently asked questions

What does Centauri Therapeutics do?: Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets. The platform is intended for treatment of life-threatening indications across multiple disease areas.
Who are Centauri Therapeutics's investors?: Centauri Therapeutics's investors include AMR Action Fund, NCL Technology Ventures Ltd., Boehringer Ingelheim Venture Fund.